Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.39 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.39 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.39 |
| ▸ | PLAU | P00749 | 1/20 | 0.38 |
| ▸ | GLA | P06280 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | CA9 | Q16790 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | IP6K1 | Q92551 | 1/20 | 0.36 |
| ▸ | IP6K3 | Q96PC2 | 1/20 | 0.36 |
| ▸ | IP6K2 | Q9UHH9 | 1/20 | 0.36 |
| ▸ | MMP13 | P45452 | 1/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | PLK1 | P53350 | 5/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2825033 | 0.88 | PLK1 (0.39) | HDAC6HDAC8HDAC2PLAUGLA | |
| SCHEMBL30526682 | 0.88 | PLK1 (0.39) | HDAC6HDAC8HDAC2PLAUGLA | |
| SCHEMBL1710487 | 0.87 | HDAC1 (0.39) | HDAC6GLACA1CA2CA9 | |
| SCHEMBL16599330 | 0.85 | TAS1R3 (0.43) | HPGDMAPK14 | |
| SCHEMBL2214140 | 0.85 | MAPK14 (0.43) | CA1CA2CA9HPGDIP6K1 | |
| SCHEMBL14217297 | 0.83 | CYP2A6 (0.38) | CA1CA2CA9HPGDHTT | |
| SCHEMBL397041 | 0.83 | TSHR (0.41) | CA1CA2CA9TSHRSMN1; SMN2 | |
| SCHEMBL21911828 | 0.82 | NPC1 (0.50) | PLAUCA1CA2CA9HPGD | |
| SCHEMBL2717824 | 0.82 | L3MBTL1 (0.45) | CA1CA2CA9HPGDSMN1; SMN2 | |
| SCHEMBL380118 | 0.82 | GLA (0.50) | GLAMEN1KMT2AMAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11566003-B2 | Isoquinolines as inhibitors of HPK1 | GENENTECH, INC. (US) | 2023-01-31 | — | — | US | disclosed |
| US-11566003-B2 | Isoquinolines as inhibitors of HPK1 | GENENTECH, INC. (US) | 2023-01-31 | — | — | US | disclosed |
| EP-3601259-B1 | ISOQUINOLINES AS INHIBITORS OF HPK1 | HOFFMANN LA ROCHE (CH) | 2022-02-23 | — | — | EP | disclosed |
| US-20210163417-A1 | ISOQUINOLINES AS INHIBITORS OF HPK1 | GENENTECH, INC. (US) | 2021-06-03 | — | — | US | disclosed |
| US-20210163417-A1 | ISOQUINOLINES AS INHIBITORS OF HPK1 | GENENTECH, INC. (US) | 2021-06-03 | — | — | US | disclosed |
| WO-2020198053-A1 | 2-OXO-2,3-DIHYDRO-1H-IMIDAZO[4,5-B]PYRIDIN-6-YL)-4-METHYLBENZAMIDE DERIVATIVES AND SIMILAR COMPOUNDS AS RIPK2 INHIBITORS FOR TREATING E.G. AUTOIMMUNE DISEASES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-10-01 | — | — | WO | disclosed |
| EP-3601259-A1 | ISOQUINOLINES AS INHIBITORS OF HPK1 | H. Hoffnabb-La Roche Ag (CH) | 2020-02-05 | — | — | EP | disclosed |
| WO-2018183964-A1 | ISOQUINOLINES AS INHIBITORS OF HPK1 | GENENTECH, INC. (US) | 2018-10-04 | — | — | WO | disclosed |
| US-20180282282-A1 | ISOQUINOLINES AS INHIBITORS OF HPK1 | GENENTECH, INC. (US) | 2018-10-04 | — | — | US | disclosed |
| EP-2258687-A1 | Nicotinamide derivates useful as P38 inhibitors | Glaxosmithkline LLC (US) | 2010-12-08 | — | — | EP | disclosed |
| WO-2008104473-A2 | PYRAZOLOPYRIIDINE DERIVATIVES AND THEIR USE AS KINASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2008-09-04 | — | — | WO | disclosed |
| WO-2008104473-A2 | PYRAZOLOPYRIIDINE DERIVATIVES AND THEIR USE AS KINASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2008-09-04 | — | — | WO | disclosed |
| US-20080207684-A1 | Kinase inhibitors and methods for using the same | ROCHE PALO ALTO LLC | 2008-08-28 | — | — | US | disclosed |
| US-20080207684-A1 | Kinase inhibitors and methods for using the same | ROCHE PALO ALTO LLC | 2008-08-28 | — | — | US | disclosed |
| US-20080207684-A1 | Kinase inhibitors and methods for using the same | ROCHE PALO ALTO LLC | 2008-08-28 | — | — | US | disclosed |
| EP-1864975-A2 | Novel compounds | SmithKline Beecham Corporation (US) | 2007-12-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080207684-A1 | Kinase inhibitors and methods for using the same | MAP3K1, MAPK1, MAP3K20 | HDAC6 607/4885HDAC8 845/4885HDAC2 548/4885 |
| US-20180282282-A1 | ISOQUINOLINES AS INHIBITORS OF HPK1 | HIPK1, HPGDS, IP6K1 | HDAC6 1907/4885HDAC8 1011/4885HDAC2 844/4885 |
| US-11566003-B2 | Isoquinolines as inhibitors of HPK1 | HIPK1, HIPK2, IP6K1 | HDAC6 1623/4885HDAC8 906/4885HDAC2 801/4885 |
| US-20210163417-A1 | ISOQUINOLINES AS INHIBITORS OF HPK1 | HIPK1, HIPK2, IP6K1 | HDAC6 1623/4885HDAC8 906/4885HDAC2 801/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.